Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to moderate coronavirus disease 2019 following either intravenous (i.v.) or intramuscular (i.m.) administration. Population ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Sager, Jennifer E., El‐Zailik, Asma, Passarell, Julie, Roepcke, Stefan, Li, Xiaobin, Aldinger, Melissa, Nader, Ahmed, Skingsley, Andrew, Alexander, Elizabeth L., Yeh, Wendy W., Mogalian, Erik, Garner, Chad, Peppercorn, Amanda, Shapiro, Adrienne E., Reyes, Maribel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272298/
https://www.ncbi.nlm.nih.gov/pubmed/36922886
http://dx.doi.org/10.1002/psp4.12958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272298/
https://www.ncbi.nlm.nih.gov/pubmed/36922886
http://dx.doi.org/10.1002/psp4.12958

Ejemplares similares